Taracena PS, Rodriguez WFL, Díaz GEJ, Guzmán VG

Language: Spanish
References: 19
Page: 12-17
PDF size: 203.00 Kb.

ABSTRACT

Introduction: recommendations call for maintaining 100-180 mg/dL serum glucose for non-critically ill patients in most settings; however, the methods for achieving these figures and the evidence supporting these recommendations are conflicting. As for the pharmacological method of control, insulin remains the first choice, although the methods of administering insulin are heterogeneous in different non-critical clinical settings. Whether bolus or basal-bolus administration scheme, the available literature maintains conflicting results. Materials and methods: in a retrospective, non-randomized, descriptive, comparative study, the incidence of hypoglycemia in two treatments for hyperglycemia control was documented to identify which has a higher risk of generating hypoglycemia in non-critical patients. Forty cases were analyzed, documenting the type of insulin regimen, demographic characteristics, and incidence of hypoglycemia. Results: more hypoglycemia events were recorded between the two groups in the basal-bolus vs. bolus group (21.5 versus 7.69%, p < 0.05). Conclusions: the data analysis suggests a higher risk of hypoglycemia in non-critically ill patients in the basal-bolus schedule, but the authors are confident that the experience gained with this protocol will allow the application of prospective studies in the future.

REFERENCES

1. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Pública Mex. 2023; 65: s163-s168.

2. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021; 9 (3): 174-188.

3. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D. et al 16. Diabetes care in the hospital: standards of care in diabetes-2023. Diabetes care. 2023; 46 (Suppl 1): S267-S278.

4. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45 (11): 2753-2786.

5. Lorenzo-González C, Atienza-Sánchez E, Reyes-Umpierrez D, Vellanki P, Davis GM, Pasquel FJ et al. Safety and efficacy of DPP-4 inhibitors for the management of hospitalized general medicine and surgery patients with type 2 diabetes. Endocr Pract. 2020; 26 (7): 722-728.

6. Jervis M, Mitchell AP, Islam N, Mustafa OG, Kelly PA, Whyte MB. GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin. Diabetes Metab Res Rev. 2022; 38 (8): e3574.

7. Estrada AK, Delgado-Maldonado T, Lara-Ramírez EE, Martínez-Vázquez AV, Ortiz-Pérez E, Paz-González AD et al. Recent advances in the development of type 2 sodium-glucose cotransporter inhibitors for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2022; 22 (4): 586-599.

8. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345 (19): 1359-1367.

9. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-1297.

10. Said E, Farid S, Sabry N, Fawzi M. Comparison on efficacy and safety of three inpatient insulin regimens for management of non-critical patients with type 2 diabetes. Pharmacol Pharm. 2013; 4 (7): 556-565.

11. Schroeder JE, Liebergall M, Raz I, Egleston R, Ben Sussan G, Peyser A et. al. Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: a randomized prospective study. Diabetes Metabol Res Rev. 2012; 28 (1): 71-75.

12. Aidar RG, Salil G, Sundae S, Limin P, Umpierrez GE. Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy. Endocr Pract. 2013; 19 (2): 231-235.

13. Webster RE, Belfer JJ, Schmidt KJ. Evaluation of basal plus versus sliding scale insulin therapy on glucose variability in critically ill patients without preexisting diabetes. Ann Pharmacother. 2024; 58 (6): 565-571.

14. Cheung NW, Chipps DR. Sliding scale insulin: will the false idol finally fall? Intern Med J. 2010; 40 (9): 662-664.

15. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007; 30 (9): 2181-2186.

16. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011 Feb;34(2):256-61.

17. Lee YY, Lin YM, Leu WJ, Wu MY, Tseng JH, Hsu MT et al. Sliding-scale insulin used for blood glucose control: a meta-analysis of randomized controlled trials. Metabolism. 2015; 64 (9): 1183-1192.

18. Colunga-Lozano LE, Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez AV, Roman Y et al. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev. 2018; 11 (11): CD011296.

19. Vellanki P, Cardona S, Galindo RJ, Urrutia MA, Pasquel FJ, Davis GM et al. Efficacy and safety of intensive versus nonintensive supplemental insulin with a basal-bolus insulin regimen in hospitalized patients with type 2 diabetes: a randomized clinical study. Diabetes Care. 2022; 45 (10): 2217-2223.